Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 10/20 | 0.58 |
| ▸ | THRA | P10827 | 2/20 | 0.51 |
| ▸ | P2RX7 | Q99572 | 8/20 | 0.48 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30504581 | 1.00 | THRB (0.58) | THRBTHRAP2RX7ESR1ESR2 | |
| SCHEMBL30504582 | 1.00 | THRB (0.58) | THRBTHRAP2RX7ESR1ESR2 | |
| SCHEMBL3348736 | 0.79 | P2RX7 (0.48) | THRBTHRAP2RX7ALDH1A1LMNA | |
| SCHEMBL1412845 | 0.79 | P2RX7 (0.59) | THRBTHRAP2RX7ALDH1A1ABCB11 | |
| SCHEMBL3348732 | 0.78 | P2RX7 (0.58) | THRBTHRAP2RX7LMNASMN1; SMN2 | |
| SCHEMBL10512600 | 0.78 | HIF1A (0.50) | THRBP2RX7ABCB11 | |
| SCHEMBL6216239 | 0.76 | THRB (0.74) | THRBTHRA | |
| SCHEMBL6217449 | 0.76 | THRB (0.74) | THRBTHRA | |
| SCHEMBL10439124 | 0.76 | NPC1 (0.55) | THRBALDH1A1MAPTHTTSMN1; SMN2 | |
| SCHEMBL16910734 | 0.74 | TP53 (0.41) | ESR1ESR2ALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116606259-B | Preparation method of Sha Mizhu key intermediate of anti-insect veterinary drug | 山东国邦药业有限公司 | 2023-09-15 | — | — | CN | claimed |
| CN-116606259-A | Preparation method of Sha Mizhu key intermediate of anti-insect veterinary drug | 山东国邦药业有限公司 | 2023-08-18 | — | — | CN | claimed |
| CN-116606259-B | Preparation method of Sha Mizhu key intermediate of anti-insect veterinary drug | 山东国邦药业有限公司 | 2023-09-15 | — | — | CN | disclosed |
| CN-116606259-B | Preparation method of Sha Mizhu key intermediate of anti-insect veterinary drug | 山东国邦药业有限公司 | 2023-09-15 | — | — | CN | disclosed |
| CN-116606259-A | Preparation method of Sha Mizhu key intermediate of anti-insect veterinary drug | 山东国邦药业有限公司 | 2023-08-18 | — | — | CN | disclosed |
| CN-116606259-A | Preparation method of Sha Mizhu key intermediate of anti-insect veterinary drug | 山东国邦药业有限公司 | 2023-08-18 | — | — | CN | disclosed |
| US-20160022689-A1 | Triazine compound for resisting coccidiosis in chickens | SHANGHAI VETERINARY RES INST CAAS (CN) | 2016-01-28 | — | — | US | disclosed |
| US-20160022689-A1 | Triazine compound for resisting coccidiosis in chickens | SHANGHAI VETERINARY RES INST CAAS (CN) | 2016-01-28 | — | — | US | disclosed |
| US-5530129-A | Process for the preparation of 1,2,4-triazine-3,5-diones | BAYER AKTIENGESELLSCHAFT (DE) | 1996-06-25 | — | — | US | disclosed |
| EP-0695743-A1 | Process for the preparation of 1,2,4-triazine-3,5-diones | BAYER AG (DE) | 1996-02-07 | — | — | EP | disclosed |
| EP-0330041-B1 | Substituted 1,2,4-trazine diones, process for their synthesis and their use | BAYER AG (DE) | 1994-04-13 | — | — | EP | disclosed |
| US-4968795-A | PARASITICIDES, ANTIPROTOZOA AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 1990-11-06 | — | — | US | disclosed |
| US-4935423-A | Antiprotozoa agent | BAYER AKTIENGESELLSCHAFT (DE) | 1990-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160022689-A1 | Triazine compound for resisting coccidiosis in chickens | SLC11A2, VIP, CUL5 | THRB 344/4885THRA 284/4885P2RX7 589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.